Structure Therapeutics Inc. has announced the launch of a Phase 1 clinical study for its lead oral small molecule, ACCG-2671, aimed at treating obesity. The San Francisco-based biopharmaceutical company, which specializes in developing innovative therapies for metabolic diseases, revealed this significant step on December 17, 2025.
Details of the Clinical Study
ACCG-2671 is designed as an amylin receptor agonist, utilizing the company’s advanced structure-based drug discovery platform. This platform focuses on harnessing the metabolic advantages of amylin biology in a conveniently administered oral medication taken once daily. The goal is to enhance scalability and improve accessibility for patients suffering from obesity.
Xichen Lin, Ph.D., Chief Scientific Officer of Structure Therapeutics, emphasized the potential of amylin-based therapies in reshaping the treatment landscape for obesity. He stated, “We believe amylin-based therapies are poised to become an important next-generation component of the treatment landscape for obesity and related conditions.”
Dr. Lin further highlighted that ACCG-2671 is the most advanced oral small molecule amylin therapy in the industry, demonstrating the capabilities of their unique GPCR structure-based drug discovery platform. This technology allows for the creation of highly selective, orally available medicines targeting G protein-coupled receptors (GPCRs).
Preclinical Data and Future Potential
Preclinical studies of ACCG-2671 have shown promising results, indicating potent target engagement and significant weight loss as a standalone treatment. Moreover, when combined with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), it has been observed to further enhance weight loss outcomes.
The drug has also exhibited a favorable safety profile and pharmacokinetics, making it suitable for once-daily dosing. This positions ACCG-2671 as a potential backbone therapy, usable alone or in conjunction with other weight loss medications.
With the initiation of this Phase 1 trial, Structure Therapeutics moves closer to potentially transforming obesity treatment. The company aims to deliver innovative solutions that not only address metabolic diseases but also enhance the quality of life for patients worldwide.
